THE INVESTOR

메뉴열기
March 29, 2024

[EQUITIES] ‘Celltrion’s biosimilar value rises’

PUBLISHED : February 22, 2018 - 10:35

UPDATED : February 22, 2018 - 10:35

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • sms

[THE INVESTOR] Celltrion’s value will be boosted by pending progresses of its biosimilars, including launch of hypodermic injection type Remsima, said Hyundai Motor Investment and Securities on Feb. 22, maintaining a “buy” recommendation and raising the target price to 360,000 won (US$333.06) from 285,000 won.




It is likely to win sales approval for Truxima and Herzuma in the US in the second half, and in the near future will be able to roll out subcutaneous injection type of Remsima and Inflectra, explained analyst Kang Yang-gu.

Clinical trials for Remsima are progressing positively as it has shown equivalence in treating Crohn’s disease with original medication Remicade and another autoimmune drug Humira, according to the analyst. 

Remsima is likely to enter the entire autoimmune treatment market after 2020, forecast Kang raising the value of the biosimilar to 26 trillion won from 18 trillion won.

Meanwhile the biopharmaceutical company’s earnings in the fourth quarter last year were in line with market consensus, coming in at 154.2 billion won, up 115.3 percent from the same period the previous year, said the analyst. 

By Hwang You-mee (glamazon@heraldcorp.com)

  • 페이스북
  • sms
최상단으로
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.